June 2025 Dashboard

Letters of intent

Increase access, improve consistency and reduce duplication

Since the pCPA's inception, **671** negotiations have reached a letter of intent (LOI), including:

- 248 for oncology drugs
- 73 for biosimilars
- 76 for expensive drugs for rare diseases (EDRD)


Savings

Lower drug costs

pCPA activities saved jurisdictions an estimated **\$4.87B** in 2024-25:


- \$3.94B from brand-name drugs
- \$935M from generic drugs

Since 2010, cumulative savings are estimated to be \$28.8B



HTA and pCPA volumes

• There has been very high activity in the first four months of 2025, and the pCPA is projecting record volumes of health technology assessment (HTA) recommendations, negotiations engaged and negotiations closed.



pCPA activity


first time in the post-COVID era.
The pCPA is committed to further decreasing the in-

The number of files in consideration fell below 20 files for the

- consideration timeline.


 Files under consideration
- creased, with the pCPA negotiating more than 40 files at a time over the last 8 months.

• The number of active negotiations has significantly in-




All pCPA timeline metrics have improved between 2020 and 2025.

- The typical months under consideration phase fell from **5.1 months to 2.6 months, a 49 % decrease**, and active negotiation
- timelines fell from 5.5 months to 3.2 months, a 42 % decrease.
 Between 2020 and 2024, the total timeline fell from 11 months to 8 months. Data for 2025 is not yet available.
- Time under Consideration* Active Negotiation Time Total Time*



to 6 months in 2024 (2.1 months to engagement and 3.5 months for active negotiation).

Oncology total timelines in 2024 Negotiation stages in 2024



pCPA targets outlined in the brand process guidelines are approximately 2 months for file engagement, 4 months for active negotiations and 6 months combined.